| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6024976 | NOVEN | Solubility parameter based drug delivery system and method for altering drug saturation concentration |
Jan, 2014
(10 years ago) | |
| US5656286 | NOVEN | Solubility parameter based drug delivery system and method for altering drug saturation concentration |
Aug, 2014
(9 years ago) | |
| US5646286 | NOVEN | Palladium catalyzed vinylic substitution reactions with 2-substituted-pyridines |
Aug, 2014
(9 years ago) | |
| US9724310 | NOVEN | Transdermal estrogen device and delivery |
Jul, 2028
(4 years from now) | |
| US8231906 | NOVEN | Transdermal estrogen device and delivery |
Jul, 2030
(6 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6841716 | NOVEN | Patch |
Apr, 2020
(4 years ago) | |
| US9730900 | NOVEN | Transdermal estrogen device and delivery |
Jul, 2028
(4 years from now) | |
| US9833419 | NOVEN | Transdermal estrogen device and delivery |
Jul, 2028
(4 years from now) | |
Minivelle is owned by Noven.
Minivelle contains Estradiol.
Minivelle has a total of 8 drug patents out of which 4 drug patents have expired.
Expired drug patents of Minivelle are:
- US6841716
- US6024976
- US5656286
- US5646286
Minivelle was authorised for market use on 23 September, 2014.
Minivelle is available in film, extended release;transdermal dosage forms.
Minivelle can be used as a method for administering estradiol comprising a monolithic transdermal drug delivery system consisting of (i) a backing layer and (ii) a single adhesive polymer matrix layer as claimed in us patent no. 9730900.
The generics of Minivelle are possible to be released after 04 July, 2030.
Drugs and Companies using ESTRADIOL ingredient
Market Authorisation Date: 23 September, 2014
Treatment: A method for administering estradiol comprising a monolithic transdermal drug delivery system consisting of (i) a backing layer and (ii) a single adhesive polymer matrix layer as claimed in us patent ...
Dosage: FILM, EXTENDED RELEASE;TRANSDERMAL
MINIVELLE family patents
